Post-streptococcal glomerulonephritis associated with atypical hemolytic uremic syndrome: to treat or not to treat with eculizumab?

A 7-year-old male with poststreptococcal glomerulonephritis (PSGN) developed hemolytic uremic syndrome (HUS) and achieved remission. He was treated with eculizumab for 1 year. The eculizumab was discontinued and the patient remained in remission. This is the 10th reported case of PSGN associated wit...

Descripción completa

Detalles Bibliográficos
Autores principales: Kakajiwala, Aadil, Bhatti, Tricia, Kaplan, Bernard S., Ruebner, Rebecca L., Copelovitch, Lawrence
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2016
Materias:
Glomerulonephritis
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4720198/
https://www.ncbi.nlm.nih.gov/pubmed/26798467
http://dx.doi.org/10.1093/ckj/sfv119
Descripción
Sumario:A 7-year-old male with poststreptococcal glomerulonephritis (PSGN) developed hemolytic uremic syndrome (HUS) and achieved remission. He was treated with eculizumab for 1 year. The eculizumab was discontinued and the patient remained in remission. This is the 10th reported case of PSGN associated with HUS. The histopathological feature observed at the 1-year follow-up was indistinguishable from the expected findings in an individual with healed PSGN without associated HUS. The relatively good prognosis in most prior cases and the absence of any reported recurrences strongly suggest that this form of atypical HUS does not warrant long-term eculizumab therapy.

Ejemplares similares